This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals globally, excluding the UK.
Join leading respiratory and sleep medicine expert Prof Brendon Yee for an accredited virtual webinar on applying Obstructive Sleep Apnea (OSA) screening tools and diagnostic pathways in primary care. This content has been designed to be specific to Australia. This session empowers healthcare providers to confidently navigate the shifting landscape of OSA management, utilizing Home Sleep Apnea Testing (HSAT) and validated questionnaires to streamline patient care and reduce specialist wait times.
This is Module Three of Three. Modules One and Two can be found here.
Session Highlights
- Primary Care Management: Discover how the landscape of OSA care is shifting, empowering primary care physicians to lead timely assessments and manage uncomplicated cases directly, significantly reducing specialist wait times.
- Validated Screening Tools: Master the application of high-sensitivity questionnaires like STOP-BANG, OSA-50, and the Epworth Sleepiness Scale to effectively risk-stratify patients and identify those requiring further diagnostic testing.
- Navigating Sleep Studies: Learn to select the appropriate level of sleep study—from the gold-standard, in-lab Level 1 polysomnography for complex patients to resource-efficient Level 3 or 4 Home Sleep Apnea Tests (HSAT) for uncomplicated, moderate-to-severe cases.
- Structured Diagnostic Pathways: Implement a clear, step-by-step diagnostic pathway to confidently escalate patients from a positive clinical screen to appropriate testing, specialist referral, or targeted intervention.
Who Should Watch
This program is designed for healthcare professionals globally involved in the frontline screening, diagnosis, and long-term clinical management of obstructive sleep apnea (OSA) including:
- Primary Care Physicians (General Practitioners)
- Sleep Specialists
Visual Learner? See our Infographic here
Faculty
Professor Brendon Yee, MBChB, FRACP, PhD is a Staff Specialist in Respiratory and Sleep Medicine and the Medical Director of Respiratory Failure Services at Royal Prince Alfred Hospital, as well as a consultant for Rural Outreach Services in Central Western New South Wales. A graduate of the University of Otago, New Zealand, he completed sleep fellowships in Wellington and Sydney before earning a PhD for his research on the metabolic effects of sleep apnea and weight loss. Reflecting his commitment to the field, Professor Yee is a former Australasian Sleep Association Young Investigator Award winner and has held prominent leadership roles, including serving as the past Chair of the Professional Standards Committee of the Thoracic Society of Australia and New Zealand and as a member of the Clinical Committee of the Australasian Sleep Association.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Prof Brendon Yee has the following relevant financial relationships: Speakers fee for Somnomed, Teva, Alkermes, Prof Brendon Yee discloses being a speaker and Advisory board member for Eli-Lilly.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until July 27th 2027. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information
There is no fee for this educational activity.
This continuing education activity is active starting September 9th 2026, and will expire on July 27th 2027.